Link Between Sleep Apnea and Parkinson’s Disease Found
A significant new study highlights a concerning connection between untreated sleep apnea and a heightened risk of developing Parkinson’s disease. Researchers from Oregon Health & Science University (OHSU) surveyed over 11 million veterans aged 40 and older who did not initially have Parkinson’s disease.
Among them, some were diagnosed with obstructive sleep apnea, a condition causing intermittent breathing disruptions during sleep. The study followed these individuals for nearly five years to see who would develop Parkinson’s disease.
The researchers also focused on veterans who started continuous positive airway pressure (CPAP) therapy within two years of their sleep apnea diagnosis. They aimed to determine if early intervention made any difference in Parkinson’s disease outcomes compared to those who began treatment later or not at all.
Dr. Greg Scott, a pathologist from Oregon and a co-author of the study, expressed that the findings were “remarkable.” He pointed out that those with Parkinson’s who used CPAP therapy experienced fewer fractures, falls, and lower mortality rates. “We rigorously tested this, and the results were consistent,” he added.
Published in JAMA Neurology, the study relied on records from U.S. veterans treated by the Department of Veterans Affairs between 1999 and 2022. The researchers made adjustments for various demographic and health factors, including age, gender, race, and smoking status.
The data indicated that veterans with untreated sleep apnea were almost twice as likely to develop Parkinson’s disease as those without the condition. Over the five-year period, this meant an increase of about 1 to 2 cases of Parkinson’s disease per 1,000 individuals.
Interestingly, those who initiated CPAP therapy early had approximately a 30% lower risk of developing Parkinson’s. This reduction equates to around 2.3 fewer cases of Parkinson’s disease per 1,000 people, suggesting that treating sleep apnea early could prevent one case of Parkinson’s disease for every 439 patients treated over five years.
“The most effective approach to combating neurodegenerative diseases is to focus on prevention and early detection of risk factors before significant damage occurs,” Scott stated.
Several mechanisms have been proposed to explain the observed association between sleep apnea and neurodegeneration. For example, repeated oxygen drops during sleep might harm neurons, escalate inflammation, hinder the brain’s waste removal processes, and promote the accumulation of toxic proteins.
Dr. Lee Nielson, OHSU’s neurologist and lead author of the study, explained, “When breathing halts repeatedly, your brain cells essentially experience fainting episodes.” He added that CPAP machines might mitigate these issues by stabilizing oxygen levels and enhancing sleep continuity, potentially safeguarding brain tissue over the long term.
While the study establishes a link between sleep disorders and neurological issues, the authors emphasize that it does not definitively prove causation. Being observational, it merely illustrates correlations, and the research lacked comprehensive data on patients’ consistent use of CPAP machines. Moreover, the majority of the veteran cohort were older men, which may limit the applicability of the findings to other demographics.
Additionally, researchers acknowledged that early symptoms of Parkinson’s disease, such as sleep disturbances, could lead to a diagnosis of sleep apnea in the first place.
